Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cenna Biosciences Inc.

Putting a new spin on amyloid beta target in AD

Executive Summary

Cenna Biosciences thinks it has come up with a way to target amyloid beta that will succeed where other companies have failed in Alzheimer’s disease. The San Diego-based start-up has developed technology that creates peptide drug candidates that bind the amyloid precursor protein, to prevent amyloid beta buildup in the first place.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT038386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel